These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 20347059

  • 1. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
    Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, Watts DM, Hayman E, Guertin P, Makowiecki J, Crowell J, Levesque P, Bowick GC, Morin M, Fowler E, Trent DW.
    Vaccine; 2010 May 14; 28(22):3827-40. PubMed ID: 20347059
    [Abstract] [Full Text] [Related]

  • 2. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P.
    J Infect Dis; 2003 Oct 15; 188(8):1213-30. PubMed ID: 14551893
    [Abstract] [Full Text] [Related]

  • 3. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.
    Gaspar LP, Mendes YS, Yamamura AM, Almeida LF, Caride E, Gonçalves RB, Silva JL, Oliveira AC, Galler R, Freire MS.
    J Virol Methods; 2008 Jun 15; 150(1-2):57-62. PubMed ID: 18420285
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
    Belmusto-Worn VE, Sanchez JL, McCarthy K, Nichols R, Bautista CT, Magill AJ, Pastor-Cauna G, Echevarria C, Laguna-Torres VA, Samame BK, Baldeon ME, Burans JP, Olson JG, Bedford P, Kitchener S, Monath TP.
    Am J Trop Med Hyg; 2005 Feb 15; 72(2):189-97. PubMed ID: 15741556
    [Abstract] [Full Text] [Related]

  • 7. An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures.
    Pereira RC, Silva AN, Souza MC, Silva MV, Neves PP, Silva AA, Matos DD, Herrera MA, Yamamura AM, Freire MS, Gaspar LP, Caride E.
    Vaccine; 2015 Aug 20; 33(35):4261-8. PubMed ID: 25862300
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial.
    Pfister M, Kürsteiner O, Hilfiker H, Favre D, Durrer P, Ennaji A, L'Age-Stehr J, Kaufhold A, Herzog C.
    Am J Trop Med Hyg; 2005 Mar 20; 72(3):339-46. PubMed ID: 15772332
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG, Testori M, Cheminay C, Volkmann A.
    Front Immunol; 2018 Mar 20; 9():1756. PubMed ID: 30116244
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.
    Amanna IJ, Thomas A, Engelmann F, Hammarlund E, Raué HP, Bailey AL, Poore EA, Quintel BK, Lewis AD, Axthelm MK, Johnson AL, Colgin LMA, Diamond MS, Messaoudi I, Slifka MK.
    Cell Rep Med; 2024 Jul 16; 5(7):101655. PubMed ID: 39019010
    [Abstract] [Full Text] [Related]

  • 12. Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblasts: yields, thermo and genetic stability, attenuation and immunogenicity.
    Freire MS, Mann GF, Marchevsky RS, Yamamura AM, Almeida LF, Jabor AV, Malachias JM, Coutinho ES, Galler R.
    Vaccine; 2005 Mar 31; 23(19):2501-12. PubMed ID: 15752837
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
    Piras-Douce F, Broudic K, Chautard E, Raynal F, Courtois V, Gautheron S, Mantel N.
    Vaccine; 2023 Feb 17; 41(8):1457-1470. PubMed ID: 36702693
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models.
    Tottey S, Shoji Y, Jones RM, Chichester JA, Green BJ, Musiychuk K, Si H, Manceva SD, Rhee A, Shamloul M, Norikane J, Guimarães RC, Caride E, Silva ANMR, Simões M, Neves PCC, Marchevsky R, Freire MS, Streatfield SJ, Yusibov V.
    Am J Trop Med Hyg; 2018 Feb 17; 98(2):420-431. PubMed ID: 29231157
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Is it time for a new yellow fever vaccine?
    Hayes EB.
    Vaccine; 2010 Nov 29; 28(51):8073-6. PubMed ID: 20971115
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.